Role of cellular L-arginine uptake and nitric oxide production on renal blood flow and arterial pressure regulation

Current Opinion in Nephrology and Hypertension

Volumn 22, Issue 1, 2013, Pages 45-50

  Rajapakse, Niwanthi W ^a   Mattson, David L ^b  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

hypertension; kidney; L Arg transport; nitric oxide

Indexed keywords

AMINO ACID TRANSPORTER; ANGIOTENSIN II; ARGININE; LOSARTAN; NITRIC OXIDE;

BIOAVAILABILITY; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CELL MEMBRANE; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; ENZYME ACTIVITY; EPITHELIUM CELL; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; KIDNEY BLOOD FLOW; KIDNEY FUNCTION; KIDNEY INJURY; KIDNEY PERFUSION; KIDNEY TUBULE ABSORPTION; MEAN ARTERIAL PRESSURE; PRIORITY JOURNAL; PROTEIN TRANSPORT; REVIEW;

ARGININE; BLOOD PRESSURE; ENDOTHELIUM; HUMANS; HYPERTENSION; NITRIC OXIDE; RENAL CIRCULATION;

EID: 84871774231     PISSN: 10624821     EISSN: 14736543     Source Type: Journal    
DOI: 10.1097/MNH.0b013e32835a6ff7     Document Type: Review

References (47)

1. Brosnan ME, Brosnan JT. Renal arginine metabolism. J Nutrition 2004; 134:2791S-2797S.
2. Forstermann U, Sessa WC. Nitric oxide synthases: regulation and function. Eur Heart J 2012; 33:829-837.
3. Chin-Dusting JP, Willems L, Kaye DM. L-Arginine transporters in cardiovascular disease: a novel therapeutic target. Pharmacol Ther 2007; 116:428-436.
4. Castillo L, Beaumier L, Ajami AM, et al. Whole body nitric oxide synthesis in healthy men determined from [15N]arginine-to-[15N]citrulline labeling. Proc Natl Acad Sci USA 1996; 93:11460-11465.
5. Forstermann U. Nitric oxide and oxidative stress in vascular disease. Pflugers Arch 2010; 459:923-939.
6. Rajapakse NW, Mattson DL. Role of L-arginine in nitric oxide production in health and hypertension. Clin Exp Pharm Physiol 2009; 36:249-255.
7. Closs EI, Scheld J-S, Sharafi M, et al. Substrate supply for nitric oxide synthase in macrophages and endothelial cells: role of cationic amino acid transporters. Mol Pharm 2000; 57:68-74.
8. Baydoun AR, Emery PW, Pearson JD, et al. Substrate-dependent regulation of intracellular amino acid concentrations in cultured bovine aortic endothelial cells. Biochem Biophys Res Comm 1990; 173:940-948.
9. Mendes Ribeiro AC, Brunini TMC, Mann GE. Abnormalities in L-arginine transport and nitric oxide biosynthesis in chronic renal and heart failure. Cardiovasc Res 2001; 49:697-712.
10. Vallance P, Leone A, Calver A, et al. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992; 339:572-575.
11. Wang H, Liu J. Plasma asymmetric dimethylarginine and L-arginine levels in Chinese patients with essential hypertension without coronary artery disease. J Cardiovasc Dis Res 2011; 2:177-180.
12. Closs EI, Basha FZ, Habermeier A, et al. Interference of L-arginine analogues with L-arginine transport mediated by the y+ carrier hCAT-2B. Nitric Oxide 1997; 1:65-73.
13. Baylis C. Nitric oxide synthase derangements and hypertension in kidney disease. Curr Opin Neph Hyperten 2012; 21:1-6.
14. McDonald KK, Zharikov S, Block ER, et al. A caveolar complex between the cationic amino acid transporter 1 and endothelial nitric-oxide synthase may explain the 'arginine paradox'. J Biol Chem 1997; 272:31213-31216.
15. Kakoki M, Kim H-S, Edgell C-JS, et al. Amino acids as modulators of endothelium-derived nitric oxide. Am J Physiol 2006; 291:F297-F304.
16. Wu F, Cholewa B, Mattson DL. Characterization of L-arginine transporters in rat renal inner medullary collecting duct. Am J Physiol 2000; 278:R1506-R1512.
17. Aulak KS, Liu J, Wu J, et al. Molecular sites of regulation of expression of the rat cationic amino acid transporter gene. J Biol Chem 1996; 271:29799-29806.
18. Closs EI, Albritton LM, Kim JW, et al. Identification of a low affinity high capacity transporter of cationic amino acids in mouse liver. J Biol Chem 1993; 268:7538-7544.
19. Closs EI, Graf P, Habermeier A, et al. Human cationic amino acid transporters hCAT-1, h-CAT 2A, and hCAT-2B: three related carriers with distinct transport properties. Biochemistry 1997; 36:6462-6468.
20. Hosokawa H, Sawamura T, Kobayashi S, et al. Cloning and characterization of a brain specific cationic amino acid transporter. J Biol Chem 1997; 272: 8717-8722.
21. Kakoki M, Kim H-S, Arendshorst W, et al. L-Arginine uptake affects nitric oxide production and blood flow in the renal medulla. Am J Physiol 2004; 287:R1478-R1485.
22. Dallinger S, Sieder A, Strametz J, et al. Vasodilator effects of L-arginine are stereospecific and augmented by insulin in humans. Am J Physiol 2003; 284:E1106-E1111.
23. Ruiz M. L-arginine-induced glomerular hyperfiltration response: the roles of insulin and ANGII. Am J Physiol 2008; 294:R1744-R1751.
24. Mattson DL. Importance of the renal medullary circulation in the control of sodium excretion and blood pressure. Am J Physiol 2003; 284:R13-R27.
25. Rajapakse NW, Kuruppu S, Hanchapola I, et al. Evidence that renal arginine transport is impaired in spontaneously hypertensive rats. Am J Physiol 2012; 302:F1554-F1562.
26. Kakoki M, Wang W, Mattson DL. Cationic amino acid transport in the renal medulla and blood pressure regulation. Hypertension 2002; 39:287-292.
27. Hsu CN, Huang LT, Lau YT, et al. The combined ratios of L-arginine and asymmetric and symmetric dimethylarginine as biomarkers in spontaneously hypertensive rats. Translat Res 2012; 159:90-98.
28. Portaluppi F, Boari B,Manfredini R. Oxidative stress in essential hypertension. Curr Pharm Des 2004; 10:1695-1698.
29. Li H, Forstermann U. Nitric oxide in the pathogenesis of vascular disease. J Path 2000; 190:244-254.
30. Majid DSA, Kopkan L. Nitric oxide and superoxide interactions in the kidney and their implication in the development of salt-sensitive hypertension. Clin Exp Pharm Physiol 2007; 34:946-952.
31. Romero JC, Reckelhoff JF. Role of angiotensin and oxidative stress in essential hypertension. Hypertension 1999; 34:943-949.
32. Rajapakse NW, De Miguel C, Das S, et al. Exogenous L-arginine ameliorates angiotensin II induced hypertension and renal damage in rats. Hypertension 2008; 52:1084-1090.
33. Rajapakse NW, Mattson DL. Role of L-arginine uptake mechanisms in renal blood flow responses to angiotensin II in rats. Acta Physiologica 2011; 203:391-400.
34. Hultstrom M, Helle F, Iversen BM. AT1 receptor activation regulates the mRNA expression of CAT1, CAT2, arginase 1, and DDAH2 in preglomerular vessels from angiotensin II hypertensive rats. Am J Physiol 2009; 297:F163-F168.
35. Dumount Y, D'Amours M, Lebel M, et al. Supplementation with a low dose of L-arginine reduces blood pressure and endothelin-1 production in hypertensive uraemic rats. Nephrol Dial Transplant 2001; 16:746-754.
36. Piatti P, Fragasso G, Monti LD, et al. Acute intravenous L-arginine infusion decreases endothelin-1 levels and improves endothelial function in patients with angina pectoris and normal coronary arteriograms: correlation with asymmetric dimethylarginine levels. Circulation 2003; 107:429-436.
37. Kelly LK, Wedgwood S, Steinhorn RH, et al. Nitric oxide decreases endothelin-1 secretion through the activation of soluble guanylate cyclase. Am J Physiol 2004; 286:L984-L991.
38. Laplante MA, Wu R, Moreau P, et al. Endothelin mediates superoxide production in angiotensin II-induced hypertension in rats. Free Radic Biol Med 2005; 38:589-596.
39. Wascher TC, Posch K, Wallner S, et al. Vascular effects of L-arginine: anything beyond a substrate for the NO-synthase? Biochem Biophys Res Comm 1997; 234:35-38.
40. Chowienczyk P, Ritter J. Arginine: NO more than a simple aminoacid? Lancet 1997; 350:901-902.
41. Barri YM, Wilcox CS. Salt intake determines the renal response to L-arginine infusion in normal human subjects. Kidney Int 1998; 53:1299-1304.
42. Higashi Y, Oshima T, Ozono R, et al. Effects of L-arginine infusion on renal hemodynamics in patients with mild essential hypertension. Hypertension 1995; 25:898-902.
43. Higashi Y, Oshima T, Watanabe M, et al. Renal response to L-arginine in saltsensitive patients with essential hypertension. Hypertension 1996; 27:643-648.
44. Dong JY, Qin LQ, Zhang Z, et al. Effect of oral L-arginine supplementation on blood pressure: a meta-analysis of randomized, double-blind, placebo-controlled trials. Am Heart J 2011; 162:959-965.
45. Schlaich MP, Parnell MM, Ahlers BA, et al. Impaired L-arginine transport and endothelial function in hypertensive and genetically predisposed normotensive subjects. Circulation 2004; 110:3680-3686.
46. Ribeiro A, Brunini T. L-Arginine transport in disease. Curr Med Chem Cardiovasc Hematol Agents 2004; 2:123-131.
47. Panza JA, Casino PR, Badar DM, et al. Effect of increased availability of endothelium-derived nitric oxide precursor on endothelium-dependent vascular relaxation in normal subjects and in patients with essential hypertension. Circulation 1993; 87:1475-1481.